Anika Therapeutics, Inc.
ANIK· Nasdaq
ANIKAnika Therapeutics, Inc.
Released Mar 13, 2024, after the close
10-K filed Mar 15, 2024, 75 days after period end · 0001171843-24-001380
derived · Computed from the longer spans the company filed.
| Metric | Q4 2023dderived from reported figures | Q4 2022dderived from reported figures | Q4 2021dderived from reported figures | Q4 2020 |
|---|---|---|---|---|
| Revenue | — | — | $35.82M | $32.69M |
| Net Income | -$63.00M | -$4.91M |
Anika Therapeutics, Inc. · CIK 898437 · Engraved from SEC EDGAR
| -$5.79M |
| -$15.66M |
| EPS Diluted | — | — | — | -$1.10 |
|---|
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
